Elevated Capital Advisors’s Labcorp LH Stock Holding History

Elevated Capital Advisors’s Portfolio LH Stock Details LH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$280	Hold	1	–	–	﹤0.01%	825
2026 Q1	$267	Hold	1	–	–	﹤0.01%	822
2025 Q4	$251	Buy	+1	New	+$266	﹤0.01%	803

Other funds holding LH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Elevated Capital Advisors's LH Position: Q2 2026 in Review

Elevated Capital Advisors held its Labcorp (LH) position steady in Q2 2026 at 1 share worth $280. The position accounts for ﹤0.01% of the portfolio, ranked #825.

Elevated Capital Advisors first reported a position in LH in Q4 2025 and has held it in 3 quarters since. 1,060 funds tracked by Wall St. Rank hold LH as of Q2 2026.

Elevated Capital Advisors held 1 share of Labcorp worth $280 as of Q2 2026.
Elevated Capital Advisors left its Labcorp share count unchanged in Q2 2026.
Labcorp made up ﹤0.01% of Elevated Capital Advisors's portfolio in Q2 2026, its #825 holding.
Elevated Capital Advisors first reported a position in Labcorp in Q4 2025 and has held it in 3 quarters since.
1,060 funds tracked by Wall St. Rank held Labcorp as of Q2 2026.

Based on Elevated Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.